An observational study in Pulmonary Arterial Hypertension (PAH) and Sleep-disordered Breathing (SDB), sponsored by Chinese Pulmonary Vascular Disease Research Group. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-01.
Sponsored by Chinese Pulmonary Vascular Disease Research Group · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 76 studies in Pulmonary Arterial Hypertension with a site in China — 19 open to participants now, 24 under way, 3 of them phase 3. Pulmonary Arterial Hypertension · China.
Among the 76 studies in Pulmonary Arterial Hypertension with a site in China, this one is the 6th largest by planned enrollment of the 20 observational ones that give a count, is one of 3 that started in 2026, is one of 20 observational ones, reaches primary completion later than 23 of the 23 other live ones, and was the 76th registered.
701 studies on the registry are indexed under Pulmonary Arterial Hypertension; 141 are open to participants now.
Browse Pulmonary Arterial Hypertension studies →19 of the 76 studies in Pulmonary Arterial Hypertension with a site in China are open now. Recruiting first, the newest first:
China National Center for Cardiovascular Diseases · Sites in China
Ages 18+
ImmuneCare Biopharmaceuticals (Shanghai) Co., Ltd. · Sites in China
Ages 18–75
Second Affiliated Hospital, School of Medicine, Zhejiang University · Sites in China
Ages 18–80
Pulnovo Medical (Wuxi) Co., Ltd. · Sites in China
Qianfoshan Hospital · Sites in China
Ages 18–80
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 90 Pulmonary Arterial Hypertension studies recruiting now, 51 (57%) set no upper age limit and 24 (27%) stop at 75 or younger; 18 take children under 18; 11 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
76 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 11 · Phase 3 27 · Phase 4 6
First in 2004; this study’s year is marked. 3 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 1,500 is above the median of 104 across 181 observational studies indexed under Pulmonary Arterial Hypertension.
Median enrollment 148 across the 56 interventional studies, 495 across the 20 observational. Of the 37 that completed or were terminated, 20 (54%) have results posted.
This tab as a report to print or save as PDF → With an account.
41 of 76 have an industry lead sponsor. The 10 most frequent:
Chinese Pulmonary Vascular Disease Research Group is the lead sponsor of 17 studies on the registry; 11 are open to participants now.
Chinese Pulmonary Vascular Disease Research Group has 5 studies filed under Pulmonary Arterial Hypertension — fewer than ten, so there is no comparison to draw.
7 of the studies in Pulmonary Arterial Hypertension with a site in China that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03683186Phase 3United TherapeuticsA Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension | 2026-12 |
| NCT05179876Phase 3ActelionA Study Providing Treatment Access in Participants With Pulmonary Hypertension Completing a Parent Study and Having no Other Option | 2027-01-31 |
| NCT06554301China National Center for Cardiovascular DiseasesA Study on the Efficacy and Safety of Empagliflozin in the Treatment of Pulmonary Arterial Hypertension | 2026-12 |
| NCT06528418ChromX HealthIdentification of Multiple Pulmonary Diseases Using Volatile Organic Compounds Biomarkers in Human Exhaled Breath | 2026-12-30 |
| NCT07184814China-Japan Friendship HospitalClinical Features and Prognosis of Takayasu's Arteritis With Pulmonary Arteries Involvement | 2026-12-31 |
Add all 7 to your calendar (.ics) → With an account.
Among the 76 studies in Pulmonary Arterial Hypertension with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Pulmonary arterial hypertension (PAH) is a progressive pulmonary vascular disease characterized by increased pulmonary vascular resistance, right ventricular dysfunction, and clinically important morbidity and mortality. Sleep-disordered breathing (SDB) and sleep-related hypoxemia are common in patients with PAH, but their prevalence, physiological determinants, longitudinal trajectories, prognostic significance, and potential role in individualized management remain incompletely defined.
PAH-SDB is a prospective, multicenter, observational patient registry enrolling adults with right-heart-catheterization-confirmed World Health Organization Group 1 PAH at pulmonary vascular centers across China. Participants will undergo standardized nocturnal sleep and cardiorespiratory monitoring together with comprehensive PAH assessment, including clinical characteristics, functional status, biomarkers, echocardiography, hemodynamics, treatment, and outcomes. Selected participants may undergo additional polysomnography, cardiac magnetic resonance imaging, wearable monitoring, repeated sleep assessments, or biospecimen collection when available and ethically approved.
The registry will characterize the prevalence and phenotypes of sleep-disordered breathing and nocturnal physiological abnormalities; examine their relationships with PAH severity and right ventricular-pulmonary vascular function; determine their value for predicting clinical worsening, hospitalization, transplantation, and mortality; evaluate longitudinal changes in sleep physiology in relation to PAH treatment and disease trajectory; and develop and validate multimodal statistical and artificial-intelligence models for phenotyping, risk prediction, and treatment-response stratification. Clinical management will remain at the discretion of treating physicians, and the registry will not assign PAH or sleep-related therapies.
PAH-SDB is designed as a disease-based prospective multicenter patient registry and longitudinal cohort. The registry addresses the interaction between sleep-disordered breathing (SDB) or nocturnal respiratory physiology and pulmonary vascular disease across the contemporary treatment era of pulmonary arterial hypertension (PAH). The study is intentionally broader than an apnea-hypopnea-index-centered cohort and will capture obstructive and central respiratory events, sustained and intermittent hypoxemia, desaturation morphology and burden, heart-rate and autonomic responses, respiratory instability, sleep fragmentation when available, and other digital physiological features derived from validated sleep or wearable devices.
Eligible participants will have WHO Group 1 PAH confirmed by right heart catheterization using contemporary hemodynamic criteria. Baseline assessment will include PAH etiology and duration, comorbidities, symptoms and WHO functional class, six-minute walk distance, natriuretic peptides and routine laboratory tests, electrocardiography, echocardiography, right-heart-catheterization variables, PAH-specific therapies, oxygen and positive-airway-pressure use, patient-reported outcomes where feasible, and a standardized overnight sleep study. The core sleep protocol will include airflow, respiratory effort, pulse oximetry, heart rate or electrocardiographic information, body position, and snoring when supported by the device. Full polysomnography will be performed in a nested subgroup according to clinical indication, center capability, or dedicated substudy protocols.
Participants will be followed longitudinally for clinical worsening, PAH-related hospitalization, therapy escalation, lung or heart-lung transplantation, and mortality. Repeated PAH assessments will be obtained according to routine clinical care, with harmonized registry time points. Repeat sleep monitoring is planned in a longitudinal subset, particularly after major changes in PAH treatment, clinically meaningful change in disease status, or initiation of sleep-related therapy. The registry will therefore support both baseline phenotype-outcome analyses and analyses of dynamic change.
Major scientific objectives are: (1) to determine the prevalence and distribution of sleep-disordered breathing and nocturnal hypoxemia in contemporary Chinese PAH; (2) to identify demographic, clinical, hemodynamic, imaging, and treatment correlates of nocturnal physiological phenotypes; (3) to quantify associations between sleep metrics and PAH severity, right ventricular structure and function, and validated risk strata; (4) to determine the incremental prognostic value of nocturnal physiological markers beyond established PAH risk tools; (5) to evaluate whether changes in sleep physiology track or precede changes in PAH status and treatment response; (6) to explore heterogeneity of associations across PAH subtypes, sex, age, body mass index, comorbidity burden, and treatment patterns; and (7) to develop and externally validate multimodal machine-learning and artificial-intelligence models for physiological endotyping, risk prediction, and individualized clinical decision support.
Registry quality procedures will include a standardized electronic case-report form, a data dictionary, investigator training, site initiation procedures, automated range and consistency checks, centralized data queries, periodic completeness reports, prespecified sleep-signal quality criteria, central or centrally supervised sleep scoring for key analyses, and adjudication of major clinical worsening events. A statistical analysis plan will be finalized before primary analyses. Conventional regression and time-to-event methods will be complemented by longitudinal mixed-effects models, internal-external validation across sites, causal-inference approaches for treatment-response analyses when appropriate, and multimodal machine-learning methods. Missing data mechanisms will be documented and addressed using prespecified statistical methods.
The registry is non-interventional. PAH therapy, oxygen therapy, positive airway pressure, and other clinical management will be prescribed by treating clinicians according to clinical judgment and prevailing guidelines. Any future substudy that prospectively assigns an intervention will be governed by a separate protocol and registered separately when required.
Consecutive adult patients with RHC-confirmed WHO Group 1 PAH receiving care at participating pulmonary vascular and cardiovascular centers in China. The registry will include newly diagnosed and prevalent PAH, with enrollment strata defined by disease duration and treatment status. Participating centers will include Fuwai Hospital and additional Chinese centers with expertise in PAH and the ability to perform standardized clinical and nocturnal physiological assessments.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adults with right-heart catheterization (RHC)-confirmed WHO Group 1 pulmonary arterial hypertension (PAH) consecutively enrolled at participating Chinese centers and followed prospectively with standardized nocturnal sleep/cardiorespiratory phenotyping and longitudinal PAH assessments.
Diagnostic Test: Standardized Overnight Sleep and Cardiorespiratory Monitoring
Participants undergo protocol-standardized nocturnal monitoring without study-assigned therapy. The core recording includes airflow, respiratory effort, oxygen saturation, pulse/heart rate, body position, and snoring when available. Full polysomnography, extended wearable monitoring, repeated sleep studies, and other physiological signals may be obtained in nested subcohorts. All sleep-related treatment decisions remain under routine clinical care.
Prevalence and phenotypic distribution of sleep-disordered breathing and nocturnal hypoxemia
Proportion of participants with sleep-disordered breathing (SDB) and its phenotypes, including obstructive sleep apnea (OSA) and central sleep apnea (CSA), together with the distribution of nocturnal hypoxemia and multidimensional sleep physiological burden. Core measures will include the apnea-hypopnea index (AHI) or respiratory event index (REI), obstructive and central respiratory event indices, oxygen desaturation index (ODI), percentage of recording time with peripheral oxygen saturation below 90% (T90), mean and minimum peripheral oxygen saturation (SpO₂), and prespecified hypoxic-burden metrics. Prevalence estimates will be reported with 95% confidence intervals.
Time frame: Baseline
Time to first clinical worsening event
Time from enrollment to the first adjudicated clinical worsening event. The primary composite is recommended to include all-cause death, lung or heart-lung transplantation, PAH-related unplanned hospitalization, atrial septostomy, or clinically driven major PAH treatment escalation/rescue therapy because of documented disease worsening. A sensitivity definition limited to hard outcomes will also be analyzed.
Time frame: From enrollment through 5 years of follow-up
All-cause mortality
Time from enrollment to death from any cause
Time frame: From enrollment through 5 years of follow-up
Transplant-free survival
Time to death or lung/heart-lung transplantation
Time frame: From enrollment through 5 years of follow-up
PAH-related hospitalization
Time to first PAH-related unplanned hospitalization and recurrent hospitalization burden
Time frame: From enrollment through 5 years of follow-up
Change From Baseline in REVEAL 2.0 Risk Score
The REVEAL 2.0 risk score will be calculated using available clinical variables according to the established REVEAL 2.0 algorithm. Higher scores indicate greater predicted mortality risk. Change from baseline will be evaluated at available follow-up assessments.
Time frame: Baseline to longitudinal follow-up through 5 years
Change From Baseline in ESC/ERS Four-Strata Risk Status
PAH risk status will be assessed using the ESC/ERS four-strata risk assessment approach and classified as low risk, intermediate-low risk, intermediate-high risk, or high risk. For longitudinal analyses, the four categories will be coded ordinally from 1 to 4, with higher values indicating greater estimated risk. Changes from baseline will be assessed during follow-up.
Time frame: Baseline to longitudinal follow-up through 5 years
Change From Baseline in WHO Functional Class
WHO functional class will be assessed according to the World Health Organization functional classification for pulmonary hypertension, ranging from Class I to Class IV. A higher class indicates greater functional limitation.
Time frame: Baseline to 3-6 months, 12 months, and annual follow-up through 5 years.
Change From Baseline in 6-Minute Walk Distance
Exercise capacity will be assessed using the 6-minute walk distance performed according to standardized clinical procedures. Change from baseline in walking distance will be evaluated during follow-up.
Time frame: Baseline to 3-6 months, 12 months, and annual follow-up through 5 years.
Change From Baseline in N-Terminal Pro-B-Type Natriuretic Peptide
Plasma N-terminal pro-B-type natriuretic peptide concentration will be recorded when measured as part of routine clinical assessment. Change from baseline will be evaluated at available follow-up assessments.
Time frame: Baseline to 3-6 months, 12 months, and annual follow-up through 5 years.
Change From Baseline in Right Atrial Pressure
Right atrial pressure will be measured by right-heart catheterization. Longitudinal change will be evaluated in participants who undergo clinically indicated repeat right-heart catheterization.
Time frame: Baseline to repeat right-heart catheterization during follow-up, up to 5 years
Change From Baseline in Mean Pulmonary Artery Pressure
Mean pulmonary artery pressure will be measured by right-heart catheterization. Longitudinal change will be evaluated when repeat right-heart catheterization data are available.
Time frame: Baseline to repeat right-heart catheterization during follow-up, up to 5 years
Change From Baseline in Pulmonary Arterial Wedge Pressure
Pulmonary arterial wedge pressure will be measured during right-heart catheterization.
Time frame: Baseline to repeat right-heart catheterization during follow-up, up to 5 years
Change From Baseline in Cardiac Index
Cardiac output will be determined during right-heart catheterization according to the standardized method used at the participating center. Cardiac index will be calculated as cardiac output indexed to body surface area.
Time frame: Baseline to repeat right-heart catheterization during follow-up, up to 5 years
Change From Baseline in Pulmonary Vascular Resistance
Pulmonary vascular resistance will be calculated from invasive hemodynamic measurements obtained during right-heart catheterization.
Time frame: Baseline to repeat right-heart catheterization during follow-up, up to 5 years
Change From Baseline in Respiratory Event Index
Respiratory event index will be calculated as the number of scored respiratory events per hour of valid recording time in participants assessed using portable cardiorespiratory monitoring.
Time frame: Baseline to repeat sleep monitoring during follow-up, up to 5 years
Change From Baseline in Apnea-Hypopnea Index
Apnea-hypopnea index will be calculated as the number of apneas and hypopneas per hour of total sleep time in participants undergoing polysomnography.
Time frame: Baseline to repeat polysomnography during follow-up, up to 5 years
Change From Baseline in Oxygen Desaturation Index
Oxygen desaturation index will be calculated as the number of qualifying oxygen desaturation events per hour of valid recording time according to the prespecified scoring criteria.
Time frame: Baseline to repeat sleep monitoring during follow-up, up to 5 years
Change From Baseline in Percentage of Recording Time With Oxygen Saturation Below 90% (T90)
T90 will be defined as the percentage of valid overnight recording time during which peripheral oxygen saturation is below 90%.
Time frame: Baseline to repeat sleep monitoring during follow-up, up to 5 years
Change From Baseline in Mean Overnight Oxygen Saturation
Mean peripheral oxygen saturation will be calculated across the valid overnight recording period.
Time frame: Baseline to repeat sleep monitoring during follow-up, up to 5 years
Change From Baseline in Minimum Overnight Oxygen Saturation
Minimum peripheral oxygen saturation will be defined as the lowest valid oxygen saturation value recorded during the overnight monitoring period after signal-quality control.
Time frame: Baseline to repeat sleep monitoring during follow-up, up to 5 years
Change From Baseline in Respiratory Event-Associated Hypoxic Burden
Respiratory event-associated hypoxic burden will quantify the cumulative area under oxygen desaturation curves associated with scored respiratory events, normalized by recording duration.
Time frame: Baseline to repeat sleep monitoring during follow-up, up to 5 years
Change From Baseline in Mean Event-Related Heart-Rate Surge
Event-related heart-rate surge will be calculated as the increase from the pre-event heart-rate baseline to the post-event peak heart rate for each qualifying respiratory event. The participant-level mean event-related heart-rate surge will be used for longitudinal analysis.
Time frame: Baseline to repeat sleep monitoring during follow-up, up to 5 years
Change From Baseline in Tricuspid Annular Plane Systolic Excursion
Tricuspid annular plane systolic excursion (TAPSE) will be measured by echocardiography as an index of right ventricular longitudinal systolic function. Change from baseline will be evaluated during longitudinal follow-up.
Time frame: Baseline to annual follow-up through 5 years.
Change From Baseline in Right Ventricular Fractional Area Change
Right ventricular fractional area change (RV FAC) will be assessed by echocardiography as an index of right ventricular systolic function. Change from baseline will be evaluated during longitudinal follow-up.
Time frame: Baseline to annual follow-up through 5 years.
Change From Baseline in TAPSE/sPAP Ratio
The ratio of tricuspid annular plane systolic excursion to systolic pulmonary artery pressure (TAPSE/sPAP) will be calculated from echocardiographic measurements as a noninvasive marker of right ventricular-pulmonary arterial coupling. Change from baseline will be evaluated during longitudinal follow-up.
Time frame: Baseline to annual follow-up through 5 years.
Predictive Performance of AI-Enabled Multimodal Models for Major Clinical Worsening
Artificial intelligence and machine-learning approaches will be used to derive data-driven nocturnal physiological phenotypes and to develop multimodal prediction models integrating sleep-derived signals with clinical, hemodynamic, imaging, electrocardiographic, and laboratory variables. Predictive performance for the primary longitudinal outcome of major clinical worsening will be evaluated using the area under the receiver operating characteristic curve (AUROC) in held-out or center-level validation datasets.
Time frame: From baseline assessment through 5 years of follow-up.
Treatment-Response Heterogeneity According to Baseline Sleep Phenotype
Treatment response will be evaluated according to baseline sleep-disordered breathing and nocturnal physiological phenotype. A clinically meaningful response will be defined as improvement by at least one category in the ESC/ERS four-strata PAH risk classification following initiation or escalation of PAH-targeted therapy. The proportion of participants achieving this predefined response will be compared across baseline sleep phenotypes. Analyses will account for treatment regimen, baseline disease severity, and other relevant confounders.
Time frame: From treatment initiation or escalation to the subsequent clinical reassessment, generally within 3-12 months, and through 5 years of follow-up.
Plan to share: Yes — De-identified participant-level data and a data dictionary may be shared with qualified academic investigators for scientifically sound, non-commercial research after approval by the registry Steering Committee and relevant ethics/data-governance bodies, subject to a data-use agreement and applicable Chinese regulations. Data that could enable participant re-identification will not be shared.
Supporting information: Study protocol
Time frame: Beginning after publication of the principal registry analyses and after completion of required governance review; a practical default is 12-24 months after primary publication, for a defined period specified in the approved data-use agreement.
Access criteria: Written research proposal, methodological review, investigator qualifications, ethics approval where required, data-use agreement, secure analysis environment, and commitment not to attempt re-identification or unauthorized redistribution.
Start is estimated for Oct 2026; primary completion for Dec 2031, 62 months later.
Of 64 non-industry observational studies under Pulmonary Arterial Hypertension, half reached primary completion within 60 months of starting (the median), counting those still running; a quarter within 31. This study's planned 62 months is close to that.
Counting every sponsor, half of 85 studies reached it within 58 months; a quarter within 30 and three quarters within 93.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Pulmonary Arterial Hypertension →
Chinese Pulmonary Vascular Disease Research Group